Tag
COMPASS Pathways plc
- Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial
- Compass Pathways, Hackensack Meridian Health collaborate on psilocybin treatment research
- AI shows potential for predicting psilocybin therapy outcomes: COMPASS study
- Psilocybin-like drug may help people suffering from anorexia: COMPASS study
- COMPASS Pathways reports 52% YoY cash loss
- International psychedelics market to reach US$8.3B by 2027: ReportLinker
- Filament Health to supply psilocybin for federally-funded psychedelics clinical trial